Separate names with a comma.
Bristol-Myers-Squibb announced that Amgen will acquire Celgene’s Otezla business for $13.4 billion in a cash transaction. Bristol-Myers now...
Celgene Corp. (CELG) swung to a profit in the fourth quarter from a loss last year, helped by lower research and development costs as well as a...
Bristol-Myers Squibb acquires Celgene for $74 billion. Celgene stock surges while BMY plunges. 2019 starts well for Celgene. More M&As are in...
What's the reason for Celgene going down even after beating the estimates and lifting 2018 outlook? Any thoughts?...
Celgene's second quarter results beat estimates and the company lifted 2018 outlook. Celgene will not be increasing the price of its products this...
In the past two weeks, Celgene has reported positive results from 3 clinical trials. This includes two studies with its partner Acceleron....
Just days after FDA announced a list of companies that use “gaming” tactics to delay the entry of the generic competitors, Celgene plunges to a...
Celgene reported better-than-expected first quarter results, as its flagship drug for multiple myeloma continued to increase in new and repeat...
From 1-10
Gilead Sciences (GILD) reported a 43% dip in earnings for the first quarter due to lower product sales and prescription trends. Higher competition...
It’s no big secret that investment in biotech stocks can offer great returns for investors, and at the same time, they can do some serious damage...
https://news.alphastreet.com/celgenes-potential-blockbuster-drug-filing-fails-to-pass-the-muster-with-the-fda/ “Refuse to file” letter sent to...
http://alph.st/ba1df6ff Higher sales of Revlimid and Otezla help Celgene to report better than expected sales figure. Will the two (Impact and...
It's an M&A Monday for the pharma companies. Two major pharma acquisitions announced today. 1) Celgene acquires Juno for $9 billion...
Yesterday, WSJ has stated that Celgene is holding talks to acquire Juno Therapeutics. http://alph.st/pd7bf702 Will this move strengthen Celgene?...
Celgene strengthens its cancer portfolio by acquiring Impact Biomedicines. After stopping the Crohn's disease treatment trials and cutting down...
A trial testing Revlimid on follicular lymphoma did not meet the desired endpoint. Biogen's RITUXAN also fails..
Celgene announces positive results from the trials with its development partners Bluebird Bio and Juno Therapeutics in ASH 2017. I think it's an...
http://alph.st/b9f74234 Remember, Celgene settled a lawsuit for the fraudulent use of Thalomid in July 2017 for $280 million. Now Lannett is going...
http://alphastreet.com/b0662389 Celgene's outlook, especially it's long-term targets, is not an encouraging one. Also, a decrease in pharma...
